SIG
RLMD icon

Sargent Investment Group’s Relmada Therapeutics RLMD Stock Holding History

Sargent Investment Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,670
Closed -$4.71K – 243
2024
Q4 		$4.71K Sell
11,670
-9,790
-46% -$23.9K ﹤0.01% 236
2024
Q3 		$69.5K Hold
21,460
– – 0.01% 208
2024
Q2 		$64.4K Sell
21,460
-358
-2% -$1.29K 0.01% 213
2024
Q1 		$101K Buy
+21,818
New +$105K 0.02% 193
2023
Q4 		– Sell
-16,206
Closed -$48.6K – 213
2023
Q3 		$48.6K Sell
16,206
-300
-2% -$891 0.01% 199
2023
Q2 		$40.6K Buy
16,506
+2,189
+15% +$6.05K 0.01% 197
2023
Q1 		$33.9K Buy
+14,317
New +$49.4K 0.01% 195

Other funds holding RLMD

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

Sargent Investment Group's RLMD Position: Q1 2025 in Review

Sargent Investment Group sold out of Relmada Therapeutics (RLMD) in Q1 2025, closing a stake of 11,670 shares — an estimated $4.71K sold.

Sargent Investment Group first reported a position in RLMD in Q1 2023 and held it in 7 quarters. The position peaked at $101K in Q1 2024. 44 funds tracked by Wall St. Rank hold RLMD as of Q1 2025.

  • Sargent Investment Group reported no remaining Relmada Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Sargent Investment Group sold 11,670 Relmada Therapeutics shares in Q1 2025, an estimated $4.71K.
  • Sargent Investment Group first reported a position in Relmada Therapeutics in Q1 2023 and held it in 7 quarters.
  • Sargent Investment Group's Relmada Therapeutics position peaked at $101K in Q1 2024.
  • 44 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2025.

Based on Sargent Investment Group's 13F filing for Q1 2025, filed 5 May 2025.